Veracity Capital LLC lessened its position in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 28.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,192 shares of the company's stock after selling 14,467 shares during the period. Veracity Capital LLC's holdings in Fresenius Medical Care were worth $842,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in FMS. Allworth Financial LP boosted its holdings in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company's stock valued at $36,000 after purchasing an additional 581 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Fresenius Medical Care in the third quarter valued at approximately $38,000. GAMMA Investing LLC grew its position in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company's stock worth $106,000 after buying an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC bought a new position in Fresenius Medical Care during the 3rd quarter worth $112,000. Finally, Venturi Wealth Management LLC raised its holdings in Fresenius Medical Care by 1,045.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company's stock valued at $112,000 after acquiring an additional 4,800 shares in the last quarter. Institutional investors own 8.37% of the company's stock.
Fresenius Medical Care Price Performance
Fresenius Medical Care stock traded up $0.40 during midday trading on Friday, reaching $24.63. The company's stock had a trading volume of 269,315 shares, compared to its average volume of 233,921. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a market cap of $14.45 billion, a PE ratio of 20.35, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $24.67. The business has a 50-day moving average price of $22.87 and a 200-day moving average price of $21.00.
Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.36 billion. During the same period in the previous year, the firm posted $0.31 EPS. On average, sell-side analysts predict that Fresenius Medical Care AG will post 1.53 EPS for the current year.
Analyst Ratings Changes
Several analysts have recently issued reports on the company. Berenberg Bank assumed coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a "buy" rating and a $25.60 target price on the stock. StockNews.com assumed coverage on shares of Fresenius Medical Care in a report on Friday, January 3rd. They issued a "strong-buy" rating on the stock. Truist Financial upped their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Finally, Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd.
Get Our Latest Research Report on Fresenius Medical Care
Fresenius Medical Care Profile
(
Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading

Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.